Actively Recruiting
Molecular Mechanisms in Childhood B-acute Lymphoblastic Leukaemia Relapse and Non-coding RNA Role in CD9 Regulation
Led by Rennes University Hospital · Updated on 2026-01-02
50
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer affecting children, with about 20% of patients experiencing a relapse despite treatment advances. Researchers are studying the role of the protein CD9, which influences leukaemia cell movement and adhesion, to understand its connection to relapse. The study aims to explore how CD9 regulation, possibly controlled by non-coding RNAs, could serve as a marker for predicting relapses in children diagnosed with B-ALL. The study involves collecting bone and blood samples from newly diagnosed pediatric patients at three critical therapy points: at diagnosis, after the first phase of treatment, and if relapse occurs. These samples will help researchers investigate the network of non-coding RNAs that may regulate CD9 expression. This research could identify new diagnostic or prognostic markers and potential therapeutic targets related to B-ALL relapse. Participants will undergo bone and blood sampling during their routine care at specified times. Researchers will analyze these samples to study the non-coding RNA network involved in CD9 regulation over a 5-year period. The study will monitor this network as a possible factor in disease progression and relapse prediction. The total participation includes these three sampling points aligned with treatment and relapse monitoring.
CONDITIONS
Brief Title
Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Under 18 years old
- Diagnosed with B-acute lymphoblastic leukaemia
- Initial diagnosis made at the study center
- Received oral and written information about the study protocol
- Signed informed consent if capable, or legal guardian has signed consent
- Covered by a social security scheme
You will not qualify if you...
- Isolated extramedullary involvement at inclusion
- Childbearing age without effective contraception
- Adults under legal protection or deprived of liberty
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants have bone and blood samples collected during routine care at diagnosis, after the first phase of treatment, and at relapse if it occurs to study non-coding RNA networks in CD9 regulation.
3 sampling visits during routine care
Trial Site Locations
Total: 3 locations
1
CHU Angers
Angers, France
Actively Recruiting
2
CHU Brest
Brest, France
Actively Recruiting
3
CHU Rennes
Rennes, France
Actively Recruiting
Research Team
E
Elie COUSIN, Md
M
marie-laure gervais, phd
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here